Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Update on the DEFIFrance study from EHA

Mohamad Mohty • 10 Jun 2022
EHA 2022
General Defibrotide
DEFIFrance

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an update on the DEFIFrance study (NCT02851407) investigating defibrotide in patients with hepatic veno-occlusive disease (VOD) in the real-world. Overall, the study confirmed the efficacy of defibrotide for the treatment of severe VOD and showed that safety profile of this drug was similar to what was observed in clinical trials. In addition, it highlighted the importance of rapid intervention to improve the outcomes of patients suffering from this severe complication. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mohamad Mohty

CERVINO trial results and the potential role of etentamig in multiple myeloma
1:19
CERVINO trial results and the potential role of etentamig in multiple myeloma
Mohamad Mohty • 24 Sep 2026
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
7:00
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
Mohamad Mohty • 24 Sep 2026
Transitioning bispecifics into community care for myeloma: recently published guidelines
5:44
Transitioning bispecifics into community care for myeloma: recently published guidelines
Mohamad Mohty • 13 Jun 2026
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
8:13
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Mohamad Mohty • 15 May 2026

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals